08:05 AM EDT, 10/28/2025 (MT Newswires) -- Eli Lilly ( LLY ) has already manufactured billions of doses of its new weight-loss pill orforglipron ahead of US regulatory approval in anticipation of high global demand, Bloomberg reported Tuesday, citing company chief executive officer Dave Ricks as saying at an event hosted by the Economic Club of Chicago.

The company plans to submit the drug, which is part of a new wave of obesity treatments known as GLP-1 receptor agonists, to US regulators before the end of the year, the report said.

Orforglipron may also be less expensive and easier to produce than Lilly's injectable medicines, potentially making it more affordable for patients, the report said.

Lilly did not immediately reply to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)